CC
Casdin Capital Portfolio holdings
AUM
$1.1B
This Quarter Return
+8.72%
1 Year Return
+24.98%
3 Year Return
+152.8%
5 Year Return
+110.01%
10 Year Return
–
AUM
$1.5B
AUM Growth
+$1.5B
(-0.3%)
Cap. Flow
+$16.9M
Cap. Flow
% of AUM
1.13%
Top 10 Holdings %
Top 10 Hldgs %
79.2%
Holding
40
New
5
Increased
3
Reduced
5
Closed
2
Top Buys
| 1 |
Neurogene
NGNE
|
$17.6M |
| 2 |
SEPN
Septerna, Inc. Common Stock
SEPN
|
$12.7M |
| 3 |
Beam Therapeutics
BEAM
|
$11.8M |
| 4 |
Agios Pharmaceuticals
AGIO
|
$8.22M |
| 5 |
Moderna
MRNA
|
$7.28M |
Top Sells
| 1 |
Revolution Medicines
RVMD
|
$18.2M |
| 2 |
Veracyte
VCYT
|
$15.4M |
| 3 |
Alnylam Pharmaceuticals
ALNY
|
$7.06M |
| 4 |
GRAL
GRAIL, Inc. Common Stock
GRAL
|
$4.82M |
| 5 |
Relay Therapeutics
RLAY
|
$1.25M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
GeneDx Holdings
WGS
$3.72B
| $270M | 17.94% | 3,507,164 | – | – |
|
2
BioLife Solutions
BLFS
$1.2B
| $226M | 15.04% | 8,707,165 | – | – |
|
|
3
Revolution Medicines
RVMD
$7.1B
| $162M | 10.77% | 3,699,283 -415,000 | -10% | -$18.2M |
|
4
Sarepta Therapeutics
SRPT
$1.78B
| $131M | 8.69% | 1,073,500 | – | – |
|
5
Standard BioTools
LAB
$481M
| $125M | 8.3% | 71,254,677 | – | – |
|
6
Illumina
ILMN
$15.8B
| $100M | 6.67% | 750,000 | – | – |
|
7
Avidity Biosciences
RNA
$5.99B
| $59.5M | 3.96% | 2,045,000 -39,841 | -2% | -$1.16M |
|
8
Codexis
CDXS
$246M
| $38.6M | 2.57% | 8,100,000 | – | – |
|
|
9
Relay Therapeutics
RLAY
$619M
| $36.9M | 2.45% | 8,948,574 -302,534 | -3% | -$1.25M |
|
10
Exact Sciences
EXAS
$8.98B
| $36.5M | 2.43% | 650,000 | – | – |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $32.9M | 2.19% | 140,000 -30,000 | -18% | -$7.06M |
|
|
12
Beam Therapeutics
BEAM
$1.66B
| $31M | 2.06% | 1,250,000 +475,000 | +61% | +$11.8M |
|
|
13
Neurogene
NGNE
$264M
| $29.6M | 1.97% | 1,295,361 +770,745 | +147% | +$17.6M |
|
|
BPMC
14
DELISTED
Blueprint Medicines
BPMC
| $28.5M | 1.89% | 326,378 | – | – |
|
15
Intellia Therapeutics
NTLA
$1.22B
| $23.3M | 1.55% | 2,000,000 | – | – |
|
|
VERV
16
DELISTED
Verve Therapeutics
VERV
| $22.5M | 1.5% | 3,995,571 | – | – |
|
17
Denali Therapeutics
DNLI
$2.23B
| $20.2M | 1.34% | 990,000 | – | – |
|
18
Structure Therapeutics
GPCR
$1.11B
| $19M | 1.26% | 700,000 | – | – |
|
|
SEPN
19
Septerna, Inc. Common Stock
SEPN
$539M
| $12.7M | 0.84% | +553,268 | New | +$12.7M |
|
|
20
Veracyte
VCYT
$2.39B
| $10.9M | 0.73% | 276,308 -390,000 | -59% | -$15.4M |
|
21
Guardant Health
GH
$8.41B
| $10.7M | 0.71% | 350,000 | – | – |
|
22
Tenaya Therapeutics
TNYA
$184M
| $9.63M | 0.64% | 6,732,971 | – | – |
|
|
23
Agios Pharmaceuticals
AGIO
$2.19B
| $8.22M | 0.55% | +250,000 | New | +$8.22M |
|
|
24
Moderna
MRNA
$9.37B
| $7.28M | 0.48% | +175,000 | New | +$7.28M |
|
25
4D Molecular Therapeutics
FDMT
$288M
| $6.41M | 0.43% | 1,150,000 | – | – |
|